Arcellx Q3 net loss $92.9M; initiates pivotal iMMagine-1 study for CART-ddBCMA

Arcellx, Inc.

2022-Q3 EPS reported -$4.43

Net loss of $92.9M vs $17.1M in Q3 2021, driven by $63.1M non-cash Lonza lease expense.
Cash, equivalents, and marketable securities of $280.8M as of Sep 30, 2022; funds operations for at least 12 months.
Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA in relapsed/refractory multiple myeloma.
Longer-term Phase 1 CART-ddBCMA data to be presented at ASH Annual Meeting in December 2022.
Plan to initiate Phase 1 ARC-SparX trial (ACLX-002) in AML/high-risk MDS by year-end 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcellx, Inc. reported the fiscal quarter ended September 30, 2022 results: net income $92.9 million.

Period: the fiscal quarter ended September 30, 2022
Net income: $92.9 million
Result: reported results

Exact text from the filing

Net loss was $92.9 million and $17.1 million for the quarters ended September 30, 2022 and 2021, respectively.

View on SEC.gov

Browse all earnings releases →

Arcellx, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024983

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.